Evidence map›Paper›PMID 33225544›Full record

ArticleThe oncologist2021

A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.

J Randall Patrinely, Elisa Funck-Brentano, Khang Nguyen, Suthee Rapisuwon, Joe-Elie Salem, Geoffrey T Gibney, Matteo Carlino, Douglas B Johnson

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

J Randall PatrinelySchool of Medicine, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0002-0979-1625
Elisa Funck-BrentanoUniversité de Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Biomarkers in Cancerology and Hemato-oncology, Department of General and Oncologic Dermatology, Ambroise-Paré Hospital, Assistance Publique - Hôpitaux de Paris, Boulogne-Billancourt, France.
Khang NguyenDepartment of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.
Suthee RapisuwonDepartment of Medicine, Georgetown University Hospital, Washington, DC, USA.
Joe-Elie SalemDepartment of Pharmacology, Assistance Publique - Hôpitaux de Paris, Sorbonne Universités, Paris, France.
Geoffrey T GibneyDepartment of Medicine, Georgetown University Hospital, Washington, DC, USA.
Matteo CarlinoDepartment of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.
Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Georgetown University · USAssistance Publique – Hôpitaux de Paris · FRSorbonne Université · FRThe University of Sydney · AUVanderbilt University · USVanderbilt University Medical Center · USWestmead Hospital · AU

Funding

(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibitionR01CA227481 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BALKO, JUSTIN M, JOHNSON, DOUGLAS B · 2019 to 2023
$2.6M
Predicting and profiling long-term survival after immune checkpoint inhibitionK23CA204726 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B · 2016 to 2020
$756k
NCI NIH HHS K23 CA204726NCI NIH HHS R01 CA227481
6 · The paper itself

Abstract

backgroundThe objective of this work was to characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy. MATERIALS AND

methodsPatients from four medical centers were included if they presented with isolated brain metastases treated with local therapy and received adjuvant treatment with ICIs.

resultsEleven patients with median size of largest brain metastasis of 3.9 cm, treated with surgical resection (n = 8) and/or stereotactic radiosurgery (SRS; n = 6), were included. Ipilimumab/nivolumab was the adjuvant ICI used in four patients, of whom one recurred (25%) and none died, compared with three of seven (43%) who recurred and two of seven (29%) who died following adjuvant treatment with ICI monotherapy. All recurrences were intracranial.

conclusionPatients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI therapy, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially.

Indexed as

Brain NeoplasmsRadiosurgeryCombined Modality TherapyHumansImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalRetrospective StudiesImmune Checkpoint Inhibitors

Identifiers

PMID33225544
PMCPMC7930401
OpenAlexW3110318834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.